Log in

Circassia Pharmaceuticals Stock Price, News & Analysis (LON:CIR)

GBX 17.18
+0.23 (+1.36 %)
(As of 10/18/2019 04:00 PM ET)
Today's Range
Now: GBX 17.18
50-Day Range
MA: GBX 17.24
52-Week Range
Now: GBX 17.18
Volume580,314 shs
Average VolumeN/A
Market Capitalization£64.44 million
P/E RatioN/A
Dividend YieldN/A
Circassia Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of respiratory diseases. The company markets NIOX and NIOX VERO for use in asthma diagnosis and management; and Tudorza for the treatment of chronic obstructive pulmonary disease (COPD). Its pipeline products include Flixotide, Seretide, and Flovent for asthma; and various novel specialty for COPD treatments, such as Duaklir, Spiriva, Novel LABA/LAMA formulation, and novel COPD therapy formulation. Read More…

Industry, Sector and Symbol

Industry Biotechnology
Phone44 1865 405 560



Sales & Book Value

Annual Sales£47.80 million
Cash FlowGBX 5.67 per share
Book ValueGBX 27.70 per share



Market Cap£64.44 million
Next Earnings DateN/A

Receive CIR News and Ratings via Email

Sign-up to receive the latest news and ratings for CIR and its competitors with MarketBeat's FREE daily newsletter.

Circassia Pharmaceuticals (LON:CIR) Frequently Asked Questions

What is Circassia Pharmaceuticals' stock symbol?

Circassia Pharmaceuticals trades on the London Stock Exchange (LON) under the ticker symbol "CIR."

What price target have analysts set for CIR?

4 analysts have issued 12-month price objectives for Circassia Pharmaceuticals' shares. Their forecasts range from GBX 65 to GBX 110. On average, they expect Circassia Pharmaceuticals' stock price to reach GBX 79 in the next twelve months. This suggests a possible upside of 360.0% from the stock's current price. View Analyst Price Targets for Circassia Pharmaceuticals.

What is the consensus analysts' recommendation for Circassia Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Circassia Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Circassia Pharmaceuticals.

Has Circassia Pharmaceuticals been receiving favorable news coverage?

Headlines about CIR stock have trended somewhat negative recently, InfoTrie Sentiment reports. The research firm ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Circassia Pharmaceuticals earned a coverage optimism score of -1.5 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for Circassia Pharmaceuticals.

Who are some of Circassia Pharmaceuticals' key competitors?

What other stocks do shareholders of Circassia Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Circassia Pharmaceuticals investors own include Oxford BioMedica (OXB), ABZENA/PAR VTG FPD 0.002 (ABZA), Allena Pharmaceuticals (ALNA), Sound Energy (SOU), Enanta Pharmaceuticals (ENTA), Ampliphi Biosciences (APHB), Petroamerica Oil (PTA), AstraZeneca (AZN), Boohoo Group (BOO) and Cairn Energy (CNE).

Who are Circassia Pharmaceuticals' key executives?

Circassia Pharmaceuticals' management team includes the folowing people:
  • Mr. Steven Charles Andrew Harris, Co-Founder, CEO & Director (Age 52)
  • Mr. Julien Cotta, CFO, Company Sec. & Director (Age 55)
  • Dr. Roderick Peter Hafner, Sr. VP of R&D and Director (Age 53)
  • Ms. Nina Kataria, Sr. VP Global HR
  • Mr. David L. Acheson, Sr. VP of US Commercial

How do I buy shares of Circassia Pharmaceuticals?

Shares of CIR and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Circassia Pharmaceuticals' stock price today?

One share of CIR stock can currently be purchased for approximately GBX 17.18.

How big of a company is Circassia Pharmaceuticals?

Circassia Pharmaceuticals has a market capitalization of £64.44 million and generates £47.80 million in revenue each year. Circassia Pharmaceuticals employs 400 workers across the globe.View Additional Information About Circassia Pharmaceuticals.

What is Circassia Pharmaceuticals' official website?

The official website for Circassia Pharmaceuticals is http://www.circassia.co.uk/.

How can I contact Circassia Pharmaceuticals?

The company can be reached via phone at 44 1865 405 560.

MarketBeat Community Rating for Circassia Pharmaceuticals (LON CIR)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  83 (Vote Outperform)
Underperform Votes:  64 (Vote Underperform)
Total Votes:  147
MarketBeat's community ratings are surveys of what our community members think about Circassia Pharmaceuticals and other stocks. Vote "Outperform" if you believe CIR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CIR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel